<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754517</url>
  </required_header>
  <id_info>
    <org_study_id>The reaseon of serofast</org_study_id>
    <nct_id>NCT03754517</nct_id>
  </id_info>
  <brief_title>Finding the Latent Treponema Pallidum</brief_title>
  <official_title>Finding the Latent Treponema Pallidum of Syphilis With Serofast Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some syphilitic patients remain in a serologically positive state after the recommended
      therapy. Whether a serofast state could represent a persistent low-level infection by
      Treponema pallidum is still unknown. The possibility that persistent nontreponemal antibodies
      after treatment represent persistence of Treponema pallidum was raised by some investigators.
      The investigators use the Next-Generation Sequencing to test blood plasma, srum,
      cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast
      patient and other positive and negative controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some syphilitic patients remain in a serologically positive state after the recommended
      therapy. Whether a serofast state could represent a persistent low-level infection by
      Treponema pallidum is still unknown. The possibility that persistent nontreponemal antibodies
      after treatment represent persistence of Treponema pallidum was raised by some investigators.
      The investigators use the Next-Generation Sequencing to test blood plasma, serum,
      cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast
      patient and other positive and negative controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the reads of treponema pallidum</measure>
    <time_frame>30 days</time_frame>
    <description>Using the Next-Generation Sequencing to test specific genome of treponema pallidum for syphilis</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Syphilis</condition>
  <arm_group>
    <arm_group_label>Serofast status</arm_group_label>
    <description>The syphilitic patients who remain in a serologically positive state after therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated</arm_group_label>
    <description>untreated syphilis cases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serological cure</arm_group_label>
    <description>In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.
In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RPR Titer</intervention_name>
    <description>RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing</description>
    <arm_group_label>Serofast status</arm_group_label>
    <arm_group_label>Serological cure</arm_group_label>
    <arm_group_label>Untreated</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      body fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All syphilis cases.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All clinical diagnosis of syphilis cases

        Exclusion Criteria:

          -  Auto-immune disease (such as SLE)

          -  Lyme disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Li</last_name>
    <phone>01069151502</phone>
    <email>lijun35@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PekingUMCH</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Li</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>syphilis</keyword>
  <keyword>serofast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

